Smokeless Tobacco
9
1
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Influence of Authorized Smokeless Tobacco Product Modified Risk Claims II: Laboratory Assessment of Sensory and Subjective Effects
Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure
Effect of Passive Smoking on Functional Capacity, Cognition and Academic Performance in Primary School Children
Telephone Counseling for Snuff Users
Treating Smokeless Tobacco Use in Rural Veterans
Human Laboratory Study of Smokeless Tobacco Products
In-vivo Extraction of Pb, Cd and TSNA From Swedish Snus
Bupropion SR for Treating Smokeless Tobacco Use
In-vivo Extraction of Pb, Cd andTSNA From Swedish Snus